Previous / Next

[20120311. Complications of EMR/ESD (66): Bleeding (30) - aspirin (10) risk stratification by compliance]

Bleeding after ESD. 2022-10-16. ÀÌÁØÇà

Compliance°¡ ´Ù¸£¸é riskµµ ´Ù¸¦±î¿ä? ¾àÀ» Àß ¸Ô´ø ȯÀÚ°¡ Ç×Ç÷¼ÒÆÇÁ¦¸¦ ²÷¾úÀ» ¶§¿Í ¾àÀ» Àß ¸ÔÁö ¾Ê´ø ȯÀÚ°¡ Ç×Ç÷¼ÒÆÇÁ¦¸¦ ²÷¾úÀ» ¶§ À§Ç輺ÀÇ Â÷ÀÌ´Â ¾øÀ»±î¿ä?

¾î´À review¿¡µµ ¾ð±ÞµÈ ÀûÀº ¾øÁö¸¸, ¶È°°ÀÌ ¾àÀ» ²÷¾îµµ Æò¼Ò ¾àÀ» Àß ¸Ô´ø »ç¶÷ÀÌ ´õ À§ÇèÇÒ °ÍÀ̶ó´Â ¿ì·Á°¡ ÀÖ½À´Ï´Ù. ¿Ö ±×·²±î¿ä? ±Ù°Å´Â ¾ø½À´Ï´Ù¸¸, ³ª¸§´ë·Î ÃßÁ¤Çغ¸¾Ò½À´Ï´Ù.

¾àÀ» Àß ¸ÔÁö ¾Ê´ø »ç¶÷½ÉÇ÷°ü ¹®Á¦°¡ ¿¹¹æµÇÁö ¾Ê¾Æ¼­ °íÀ§Çè ȯÀÚ´Â ÀÌ¹Ì Áװųª ÇÕº´ÁõÀÌ ¹ß»ýÇÏ¿´À» °ÍÀÌ´Ù. EMR/ESD candidate´Â ½Ç»ó ½ÉÇ÷°ü Áúȯ À§ÇèÀÌ ±×¸® ³ôÁö ¾ÊÀº »ç¶÷ÀÌ´Ù (°íÀ§Ç豺Àº º´¿¡ °É·Á selected out µÊ).¿ø·¡ ÀúÀ§Ç豺À̹ǷΠ¾àÀ» ²÷¾îµµ Æò¼Ò¿Í ¸¶Âù°¡Áö·Î risk°¡ ±×¸® ³ôÁö ¾Ê´Ù.
¾àÀ» Àß ¸Ô´ø »ç¶÷½ÉÇ÷°ü ¹®Á¦°¡ Àß ¿¹¹æµÇ¾î °íÀ§Ç豺µµ °Ç°­ÇÏ°Ô Àß Áö³½´Ù. EMR/ESD candidate Áß¿¡´Â ½ÉÇ÷°üÁúȯ °íÀ§Ç豺°ú ÀúÀ§Ç豺ÀÌ ¼¯¿© ÀÖ´Ù (not selected).¾àÀ» ²÷¾î ½ÉÇ÷°ü ¿¹¹æÈ¿°ú°¡ »ç¶óÁö¸é¼­ ¼¯¿©ÀÖ´ø °íÀ§Ç豺¿¡¼­ ÇÕº´ÁõÀÌ ¹ß»ýÇÒ ¼ö ÀÖ´Ù.

±×·¸½À´Ï´Ù. ¿©±â¼­µµ selection bias°¡ ÀÛµ¿ÇÏ°í ÀÖ½À´Ï´Ù. Æò¼Ò ¾àÀ» Àß ¸Ô´ø »ç¶÷ÀÌ ¾àÀ» ²÷À¸¸é ´õ À§ÇèÇÒ ¼ö ÀÖ½À´Ï´Ù.

¾Æ½ºÇǸ°À» ¸ÅÀÏ ¸Ô¾ú´ø °Í »©°í´Â °Ç°­ÇÏ´ø »ç¶÷ÀÌ EMR/ESD¸¦ À§ÇÏ¿© ¾àÀ» ²÷°í ÁßÁõ ½ÉÇ÷°ü ÇÕº´ÁõÀÌ ¹ß»ýÇÑ´Ù¸é ȯÀÚ³ª ÀÇ»ç ¸ðµÎ¿¡°Ô ¹«Ã´ ´çȲ½º·¯¿î ÀÏÀÏ °ÍÀÔ´Ï´Ù. ¾àÀ» ²÷Áö ¾Ê°Å³ª ª°Ô ²÷À» ¼ö ¹Û¿¡ ¾ø´Ù°í »ý°¢ÇÕ´Ï´Ù.

¾Æ½ºÇǸ°À» ²÷¾úÀ» ¶§ hypercoagulable state°¡ µÈ´Ù´Â ¿ì·Áµµ ÀÖÀ¸³ª ±Ù°Å´Â ãÁö ¸øÇß½À´Ï´Ù. Ȥ½Ã ¹®ÇåÀ» ¾Ë°í °è½Å ºÐÀº Á¦°Ô ¾Ë·ÁÁÖ½Ã¸é °¨»çÇÏ°Ú½À´Ï´Ù.


¿©·¯ºÐÀÌ Èï¹Ì·Î¿î °ü·Ã ³í¹®À» ¾Ë·ÁÁּ̽À´Ï´Ù. ´ë´ÜÈ÷ °¨»çÇÕ´Ï´Ù.

Sibon°ú Orgogozo´Â "All cases occurred between 6 and 10 days after drug discontinuation."¶ó°í ¾²°í ÀÖ½À´Ï´Ù. ±×·¸½À´Ï´Ù. ¾à ²÷°í 7ÀÏÀÌ¸é ¹«Ã´ À§ÇèÇØÁý´Ï´Ù.

Burger µîµµ ºñ½ÁÇÑ ¿¬±¸¸¦ ÇÏ¿´´Âµ¥ À§ ¿¬±¸º¸´Ù´Â ¾à°£ time intervalÀÌ ±æ¾ú½À´Ï´Ù. ÃÊ·ÏÀÇ ÀϺθ¦ ¿Å±é´Ï´Ù. "The time interval between discontinuation and acute cerebral events was 14.3 +/- 11.3 days, 8.5 +/- 3.6 days for acute coronary syndromes, and 25.8 +/- 18.1 days for acute peripheral arterial syndromes (P < 0.02 versus acute coronary syndromes)."

Doutremepuich µî ÇÁ¶û½º ¿¬±¸ÀÚµéÀÌ µÎ °³ÀÇ ³í¹®À» ¹ßÇ¥ÇÏ¿´½À´Ï´Ù (³í¹® 1°ú ³í¹® 2). ÀúÀÚµéÀÇ ÁÖÀåÀ» ¿Å±é´Ï´Ù. AspirinÀÌ ultra low dose·Î ³²À¸¸é ("ultra-low dose aspirin, ULDA")selective COX-2 inhibition°ú ºñ½ÁÇÏ°Ô µÇ¾î¼­ ¿ÀÈ÷·Á prothromboticÇÏ´Ù´Â storyÀÔ´Ï´Ù.
- What is known about this topic? Observational evidence suggests that around 10 days after aspirin discontinuation, an increased risk of a thrombotic event is observed. The risk of late stent thrombosis is also increased and is more severe for aspirin discontinuation than for thyenopiridines.
- What does this paper add? The thrombotic risk was reproduced experimentally in the rat after a single dose of aspirin 8 and 10 days after injection. These findings support the association of an increased thrombotic risk with the effect of residual levels of aspirin by acting through a COX 2 pathway. The possibility of a direct effect of aspirin rather than a rebound effect is also raised.

Acute coronary syndrome¿¡¼­ heparinÀ» ²÷À¸¸é ÀϽÃÀûÀ¸·Î hypercoagulable state°¡ µË´Ï´Ù (link). ¸®ºä¾î´Â ÀÌ·¸°Ô ¾²°í ÀÖ½À´Ï´Ù. "Longer duration of combined antiplatelet and anticoagulant treatments, e.g., until healing of the culprit lesion or even until stabilization of vulnerable, yet nondisrupted plaques, may improve long-term clinical outcome." Áï heparinÀ» »ó´çÈ÷ ¿À·¡ ¾²´Â °ÍÀÌ ÁÁ°Ú´Ù´Â ÀÇ°ßÀε¥ Kontnyµµ ºñ½ÁÇÑ À̾߱⸦ ÇÏ°í ÀÖ½À´Ï´Ù.

Ç×Ç÷¼ÒÆÇÁ¦¸¦ ¾²¸é¼­ ESD¸¦ Çصµ Å« ¹®Á¦°¡ ¾ø´Ù´Â ¼­¿ï´ëº´¿øÀÇ °á°ú°¡ EpubÀ¸·Î ³ª¿Í ÀÖ½À´Ï´Ù.


[Âü°í ÀÚ·á]

1) EndoTODAY ¿ÍÆĸ°

2) Ç×Ç÷¼ÒÆÇÁ¦ Antiplatelets - ³»½Ã°æ ȤÀº Á¶Á÷°Ë»ç Àü ¾Æ½ºÇǸ°, Ç×Ç÷¼ÒÆÇÁ¦¸¦ ²÷À» °ÍÀΰ¡?

3) »õ·Î¿î Ç×ÀÀ°íÁ¦ New oral anticoagulant (NOAC)

4) Ç×Ç÷¼ÒÆÇÁ¦, Ç×ÀÀ°íÁ¦ Áß´Ü Áöħ (»ï¼º¼­¿ïº´¿ø 2011)

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà